AZN, AMGN And BIIB, Pushing Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,918 as of Monday, June 23, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,480 issues advancing vs. 1,509 declining with 147 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Regeneron Pharmaceuticals ( REGN), down 3.0%, Alexion Pharmaceuticals ( ALXN), down 2.1%, Grifols ( GRFS), down 1.9%, Smith & Nephew ( SNN), down 1.8% and Novo Nordisk A/S ( NVO), down 1.3%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. AstraZeneca ( AZN) is one of the companies pushing the Health Care sector lower today. As of noon trading, AstraZeneca is down $0.99 (-1.3%) to $74.48 on light volume. Thus far, 1.3 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 5.4 million shares. The stock has ranged in price between $74.27-$74.73 after having opened the day at $74.44 as compared to the previous trading day's close of $75.47.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $95.1 billion and is part of the drugs industry. Shares are up 27.1% year-to-date as of the close of trading on Friday. Currently there is 1 analyst that rates AstraZeneca a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Amgen ( AMGN) is down $2.34 (-1.9%) to $118.63 on light volume. Thus far, 1.3 million shares of Amgen exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $118.57-$120.85 after having opened the day at $120.68 as compared to the previous trading day's close of $120.97.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $89.2 billion and is part of the drugs industry. Shares are up 6.0% year-to-date as of the close of trading on Friday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Biogen Idec ( BIIB) is down $4.88 (-1.5%) to $314.71 on light volume. Thus far, 489,721 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $313.25-$321.89 after having opened the day at $318.01 as compared to the previous trading day's close of $319.59.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $74.0 billion and is part of the drugs industry. Shares are up 14.3% year-to-date as of the close of trading on Friday. Currently there are 13 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

AstraZeneca Stock Gains as Crestor Sales Decline Slows

AstraZeneca Stock Gains as Crestor Sales Decline Slows

FDA Approves AstraZeneca's Blood Cancer Drug

FDA Approves AstraZeneca's Blood Cancer Drug